Mtx vacuna covid

Methotrexate may decrease effectiveness of Pfizer-BioNTech COVID-19 vaccine

According to a study published in the Annals of the Rheumatic Diseases, patients with immune-mediated inflammatory diseases (IMIDs) taking methotrexate, had an adversely affected humoral and cellular immune response to COVID-19 mRNA vaccines. Patients with IMID receiving the BNT162b2 mRNA vaccination were assessed at baseline and after the second immunization while healthy subjects served as controls.

[Dupilumab and inflammatory arthritis? Read more inDermWorld Insights and Inquiries.]

While healthy subjects and IMID patients on biologic treatments (primarily TNF blockers) demonstrated robust antibody responses (over 90%), the patients with IMID on background methotrexate achieved an adequate response in only 62% of cases. IMID patients did not demonstrate an increase in CD8+ T cell activation after vaccination. The study authors conclude that different strategies may need to be explored in patients with IMID taking methotrexate to increase chances of immunization efficacy.

Related content:

• COVID-19 vaccine information

• COVID-19 Dermatology Registry

• Methotrexate toxicity – DermWorld Insights and Inquiries (August 2017)

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.